Halozyme Therapeutics IncNASDAQ:HALO
- LAST PRICE57.2400
- TODAY'S CHANGE (%)0.2700 (0.4739%)
- Bid / Lots56.1000/ 1
- Ask / Lots58.5000/ 2
- Open / Previous Close56.8700 / 56.9700
- Day Range
- 52 Week Range
- Volume960,938
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HALO |
|---|---|---|
| 09:32 ET | 10456 | 56.95 |
| 09:34 ET | 2600 | 56.84 |
| 09:36 ET | 2773 | 56.98 |
| 09:38 ET | 7066 | 56.82 |
| 09:39 ET | 2832 | 56.995 |
| 09:41 ET | 202 | 57.08 |
| 09:43 ET | 1000 | 57.1 |
| 09:45 ET | 10492 | 57.41 |
| 09:48 ET | 900 | 57.425 |
| 09:50 ET | 718 | 57.405 |
| 09:52 ET | 878 | 57.4085 |
| 09:54 ET | 400 | 57.5 |
| 09:56 ET | 1694 | 57.46 |
| 09:57 ET | 377 | 57.48 |
| 09:59 ET | 1098 | 57.4146 |
| 10:01 ET | 883 | 57.34 |
| 10:03 ET | 22445 | 57.13 |
| 10:06 ET | 1100 | 57.215 |
| 10:08 ET | 100 | 57.19 |
| 10:10 ET | 400 | 57.36 |
| 10:12 ET | 330 | 57.44 |
| 10:15 ET | 500 | 57.55 |
| 10:17 ET | 2331 | 57.34 |
| 10:19 ET | 620 | 57.3 |
| 10:21 ET | 241 | 57.26 |
| 10:24 ET | 200 | 57.34 |
| 10:26 ET | 258 | 57.37 |
| 10:28 ET | 1040 | 57.4 |
| 10:30 ET | 638 | 57.42 |
| 10:32 ET | 339 | 57.3601 |
| 10:33 ET | 1216 | 57.4523 |
| 10:35 ET | 453 | 57.52 |
| 10:37 ET | 2007 | 57.5 |
| 10:39 ET | 1998 | 57.49 |
| 10:42 ET | 707 | 57.48 |
| 10:44 ET | 800 | 57.426 |
| 10:46 ET | 9151 | 57.395 |
| 10:48 ET | 466 | 57.408 |
| 10:50 ET | 1181 | 57.48 |
| 10:51 ET | 1400 | 57.49 |
| 10:53 ET | 1047 | 57.465 |
| 10:55 ET | 200 | 57.475 |
| 10:57 ET | 1900 | 57.47 |
| 11:00 ET | 400 | 57.455 |
| 11:02 ET | 2558 | 57.485 |
| 11:04 ET | 171 | 57.485 |
| 11:06 ET | 1200 | 57.49 |
| 11:08 ET | 3036 | 57.4453 |
| 11:09 ET | 784 | 57.45 |
| 11:11 ET | 244 | 57.425 |
| 11:13 ET | 1550 | 57.45 |
| 11:15 ET | 1963 | 57.41 |
| 11:18 ET | 416 | 57.41 |
| 11:20 ET | 100 | 57.5 |
| 11:22 ET | 1310 | 57.53 |
| 11:24 ET | 200 | 57.53 |
| 11:26 ET | 100 | 57.51 |
| 11:27 ET | 1570 | 57.4853 |
| 11:29 ET | 12563 | 57.5 |
| 11:31 ET | 554 | 57.46 |
| 11:33 ET | 600 | 57.45 |
| 11:36 ET | 5371 | 57.3 |
| 11:38 ET | 200 | 57.305 |
| 11:40 ET | 2265 | 57.285 |
| 11:42 ET | 997 | 57.25 |
| 11:44 ET | 1456 | 57.33 |
| 11:45 ET | 400 | 57.335 |
| 11:47 ET | 500 | 57.3 |
| 11:49 ET | 600 | 57.27 |
| 11:51 ET | 2339 | 57.3193 |
| 11:54 ET | 2779 | 57.25 |
| 11:56 ET | 980 | 57.215 |
| 11:58 ET | 1729 | 57.25 |
| 12:00 ET | 500 | 57.21 |
| 12:02 ET | 106 | 57.1796 |
| 12:03 ET | 300 | 57.185 |
| 12:05 ET | 385 | 57.18 |
| 12:07 ET | 400 | 57.19 |
| 12:09 ET | 7202 | 57.28 |
| 12:12 ET | 918 | 57.22 |
| 12:14 ET | 1098 | 57.178 |
| 12:16 ET | 1294 | 57.22 |
| 12:18 ET | 305 | 57.32 |
| 12:20 ET | 300 | 57.315 |
| 12:21 ET | 2506 | 57.31 |
| 12:23 ET | 2434 | 57.34 |
| 12:25 ET | 908 | 57.32 |
| 12:27 ET | 350 | 57.3475 |
| 12:30 ET | 393 | 57.3102 |
| 12:32 ET | 342 | 57.325 |
| 12:36 ET | 900 | 57.28 |
| 12:38 ET | 1417 | 57.25 |
| 12:41 ET | 400 | 57.26 |
| 12:43 ET | 300 | 57.26 |
| 12:45 ET | 706 | 57.33 |
| 12:48 ET | 1944 | 57.34 |
| 12:50 ET | 1000 | 57.3482 |
| 12:52 ET | 150 | 57.33 |
| 12:56 ET | 1537 | 57.18 |
| 12:59 ET | 300 | 57.17 |
| 01:01 ET | 878 | 57.1 |
| 01:03 ET | 198 | 57.025 |
| 01:06 ET | 1110 | 57.035 |
| 01:08 ET | 200 | 57 |
| 01:10 ET | 100 | 57.02 |
| 01:12 ET | 914 | 57.03 |
| 01:14 ET | 1753 | 57.01 |
| 01:17 ET | 356 | 56.99 |
| 01:19 ET | 100 | 56.99 |
| 01:21 ET | 300 | 56.96 |
| 01:24 ET | 500 | 57.013 |
| 01:26 ET | 855 | 57.03 |
| 01:30 ET | 700 | 56.92 |
| 01:32 ET | 253 | 56.89 |
| 01:33 ET | 100 | 56.89 |
| 01:35 ET | 2077 | 56.92 |
| 01:37 ET | 5142 | 57 |
| 01:39 ET | 1760 | 56.97 |
| 01:42 ET | 1700 | 56.9802 |
| 01:44 ET | 1127 | 56.97 |
| 01:46 ET | 1877 | 57.01 |
| 01:48 ET | 1800 | 56.95 |
| 01:50 ET | 200 | 56.93 |
| 01:53 ET | 1115 | 56.91 |
| 01:57 ET | 3878 | 56.87 |
| 02:00 ET | 876 | 56.9599 |
| 02:02 ET | 700 | 56.89 |
| 02:04 ET | 392 | 56.89 |
| 02:06 ET | 1590 | 56.82 |
| 02:08 ET | 1300 | 56.73 |
| 02:09 ET | 4271 | 56.775 |
| 02:11 ET | 1380 | 56.805 |
| 02:13 ET | 2400 | 56.73 |
| 02:15 ET | 2079 | 56.68 |
| 02:18 ET | 13494 | 56.8 |
| 02:20 ET | 1351 | 56.735 |
| 02:22 ET | 1561 | 56.67 |
| 02:24 ET | 1075 | 56.59 |
| 02:26 ET | 3570 | 56.6 |
| 02:27 ET | 944 | 56.59 |
| 02:29 ET | 1727 | 56.66 |
| 02:31 ET | 100 | 56.655 |
| 02:33 ET | 2052 | 56.64 |
| 02:36 ET | 1013 | 56.68 |
| 02:38 ET | 1936 | 56.69 |
| 02:40 ET | 470 | 56.73 |
| 02:42 ET | 2610 | 56.77 |
| 02:44 ET | 746 | 56.8 |
| 02:45 ET | 744 | 56.78 |
| 02:47 ET | 1163 | 56.84 |
| 02:49 ET | 1003 | 56.92 |
| 02:51 ET | 1784 | 56.905 |
| 02:54 ET | 1449 | 56.85 |
| 02:56 ET | 2190 | 56.85 |
| 02:58 ET | 969 | 56.875 |
| 03:00 ET | 700 | 56.89 |
| 03:02 ET | 5625 | 56.81 |
| 03:03 ET | 1727 | 56.83 |
| 03:05 ET | 1170 | 56.84 |
| 03:07 ET | 5473 | 56.84 |
| 03:09 ET | 800 | 56.87 |
| 03:12 ET | 700 | 56.86 |
| 03:14 ET | 1864 | 56.755 |
| 03:16 ET | 300 | 56.79 |
| 03:18 ET | 700 | 56.775 |
| 03:20 ET | 1460 | 56.87 |
| 03:21 ET | 1100 | 56.89 |
| 03:23 ET | 200 | 56.92 |
| 03:25 ET | 5883 | 56.97 |
| 03:27 ET | 966 | 57.02 |
| 03:30 ET | 12379 | 57 |
| 03:32 ET | 2555 | 57.095 |
| 03:34 ET | 1133 | 57.04 |
| 03:36 ET | 4142 | 57.02 |
| 03:38 ET | 2083 | 56.98 |
| 03:39 ET | 5794 | 56.91 |
| 03:41 ET | 4131 | 56.95 |
| 03:43 ET | 2589 | 56.98 |
| 03:45 ET | 1924 | 56.99 |
| 03:48 ET | 4882 | 57.05 |
| 03:50 ET | 3960 | 57.12 |
| 03:52 ET | 4200 | 57.155 |
| 03:54 ET | 6057 | 57.215 |
| 03:56 ET | 8904 | 57.225 |
| 03:57 ET | 16219 | 57.33 |
| 03:59 ET | 259161 | 57.24 |
Sep 19, 2024
DJ Halozyme Therapeutics Cut to Neutral From Overweight by JP Morgan, from 9:18AM ET on Thursday Sep 19, 2024 by Dow Jones
9:18AM ET on Thursday Sep 19, 2024 by Dow Jones
Sep 17, 2024
Sep 16, 2024
DJ Halozyme Therapeutics Price Target Maintained With a $65.00/Share by HC Wainwright & Co., from 6:58AM ET on Monday Sep 16, 2024 by Dow Jones
6:58AM ET on Monday Sep 16, 2024 by Dow Jones
Sep 13, 2024
DJ Roche Gets FDA Approval for Multiple-Sclerosis Treatment, from 2:31PM ET on Friday Sep 13, 2024 by Dow Jones
2:31PM ET on Friday Sep 13, 2024 by Dow JonesHalozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO(TM) with ENHANZE(R) for People with Relapsing and Primary Progressive Multiple Sclerosis, from 1:30PM ET on Friday Sep 13, 2024 by Dow Jones
1:30PM ET on Friday Sep 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Halozyme Therapeutics Inc | 7.9B | 22.2x | --- |
Ionis Pharmaceuticals Inc | 6.6B | -15.8x | --- |
Tempus AI Inc | 7.6B | -6.9x | --- |
Intra-Cellular Therapies Inc | 8.0B | -84.8x | --- |
Ascendis Pharma A/S | 6.9B | -15.5x | --- |
Legend Biotech Corp | 9.2B | -31.1x | --- |
Company Information
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
Contact Information
- Headquarters
- 12390 EL CAMINO REALSAN DIEGO, CA, United States 92130
- Phone
- 858-794-8889
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Jeffrey Henderson
- President, Chief Executive Officer, Director
- Helen Torley
- Chief Financial Officer, Senior Vice President
- Nicole Labrosse
- Senior Vice President, Chief Technical Officer
- Michael Labarre
- Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
- Mark Snyder
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.3B |
|---|---|
Revenue (TTM) | $873.3M |
Shares Outstanding | 126.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.27 |
EPS | $2.58 |
Book Value | $0.66 |
P/E Ratio | 22.2x |
Price/Sales (TTM) | 8.3 |
Price/Cash Flow (TTM) | 17.3x |
Operating Margin | 46.04% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
